Immune Mediated Inflammatory Diseases


This report includes analysis of three-dozen approved therapeutic drugs and late-stage development candidates that target more that a dozen discreet pathway actors, effectively reducing the human inflammatory response with fewer side effects than earlier therapeutic options.



One of the complexities of competing in the immune mediated inflammatory disease segment is the characteristic of several cytokine to exhibit an agonist effect in some environments and an antagonist effect in others. Understanding the underlying pharmacokinetics of these two distinct therapeutic effects is crucial to clinical trial success and post-approval patient acceptance.